|Articles|November 1, 2001

New Directions in the Treatment and Prevention of Deep Vein Thrombosis
Volume 7
Issue 17 Suppl

Economic Issues in the Treatment and Prevention of Deep Vein Thrombosis From a Managed Care Perspective

Author(s)Gregory de Lissovoy, PhD

Download PDF: Economic Issues in the Treatment and Prevention of Deep Vein Thrombosis From a Managed Care Perspective

Articles in this issue

over 24 years ago

Article

Participating Faculty

over 24 years ago

Article

Introduction

over 24 years ago

Article

Treatment of Deep Vein Thrombosis Using Low-Molecular-Weight Heparins

over 24 years ago

Article

Prophylaxis Strategies for Patients with Acute Venous Thromboembolism

over 24 years ago

Article

The Use of Pharmacoeconomics in Formulary Development: Can This Improve the Way Deep Vein Thrombosis is Treated?

over 24 years ago

Article

Interview

over 24 years ago

Article

Continuing Medical Education Quiz

over 24 years ago

Article

Literature Review

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

The Effect of Medicaid Reimbursement for Psychiatrists on the Health Care Burden of Serious Mental Illness

ByOnur Baser, PhD, MS,Heidi C. Waters, PhD,Nehir Yapar, BS,Gabriela Samayoa, MD, MPH,Xue Han, PhD,Deborah Freedman, MBA,Lauren Isenman, MPH,Rashmi Patel, MD, PhD

June 12th 2026

Association of Travel Nursing With Quality Outcomes in Hospitalized Patients

ByJason Bartock, MD,Adam Green, MD,Raquel Nahra, MD,Amy Bordogna, MD,Amir Davoodi, MD,Jean-Sebastien Rachoin, MD

June 11th 2026

Cost of Behavioral Messaging Interventions for Cardiovascular Medication Adherence

ByDana R. Fletcher, PhD,Lisa M. Sandy, MA,Joy Waughtal, MPH,Cole Hoffman, MS,Sylvie Novins-Montague, BA,Patrick Hosokawa, MS,Pamela N. Peterson, MD, MSPH,Larry A. Allen, MD, MPH,Sheana Bull, PhD,P. Michael Ho, MD, PhD

June 10th 2026

Changes in Persistence to Basal Insulin Following the Medicare Out-of-Pocket Cost Cap

ByRazanne Oueini, PharmD,Ben Shirley, BS,Christie Teigland, PhD,Melissa Castora-Binkley, PhD, MA,Scott Bilder, PhD,Kiran Sunkari, MS,Lynn Pezzullo, RPh

June 8th 2026

US map with stethoscope | Image Credit: © Andreas Prott - stock.adobe.com

Associations Between Socioeconomic Status, Healthy Lifestyle, and Multimorbidity in the US

ByShifeng Wu, MM

June 5th 2026

Economic Issues in the Treatment and Prevention of Deep Vein Thrombosis From a Managed Care Perspective

Articles in this issue

Related Content

The Effect of Medicaid Reimbursement for Psychiatrists on the Health Care Burden of Serious Mental Illness

Association of Travel Nursing With Quality Outcomes in Hospitalized Patients

Cost of Behavioral Messaging Interventions for Cardiovascular Medication Adherence

Changes in Persistence to Basal Insulin Following the Medicare Out-of-Pocket Cost Cap

Associations Between Socioeconomic Status, Healthy Lifestyle, and Multimorbidity in the US

Trending on AJMC

ATTR-CM Incidence, Prevalence Rose Sharply in the US

Mixed Phase 3 Results for IB6-Targeting ADC Raise Questions on Optimal Use in NSCLC

First Generic of Priftin Approved by FDA for Tuberculosis Treatment and Prevention

CDC Officially Ends Hantavirus Response as Outbreak Risk Recedes

Rewriting the AML Treatment Playbook: Tina Bhatnagar, DO

Access, Affordability, & Accountability: A New Era in Oncology Reimbursement

Economic Issues in the Treatment and Prevention of Deep Vein Thrombosis From a Managed Care Perspective

Articles in this issue

Related Content

The Effect of Medicaid Reimbursement for Psychiatrists on the Health Care Burden of Serious Mental Illness

Association of Travel Nursing With Quality Outcomes in Hospitalized Patients

Cost of Behavioral Messaging Interventions for Cardiovascular Medication Adherence

Changes in Persistence to Basal Insulin Following the Medicare Out-of-Pocket Cost Cap

Associations Between Socioeconomic Status, Healthy Lifestyle, and Multimorbidity in the US

Trending on AJMC

ATTR-CM Incidence, Prevalence Rose Sharply in the US

Mixed Phase 3 Results for IB6-Targeting ADC Raise Questions on Optimal Use in NSCLC

First Generic of Priftin Approved by FDA for Tuberculosis Treatment and Prevention

CDC Officially Ends Hantavirus Response as Outbreak Risk Recedes

Rewriting the AML Treatment Playbook: Tina Bhatnagar, DO